- This PRISMA-ScR scoping review screened 2,187 records and included 12 studies of ketamine with pain and depression outcomes assessed longitudinally.
- Eight studies enrolled chronic pain patients and four enrolled depression-primary populations, while acute, perioperative, perinatal, and cancer-related pain were excluded.
- Most studies reported concurrent improvement in pain and depressive symptoms, but the abstract gives no pooled effect size.
- The authors conclude that heterogeneity in populations, dosing, design, and comorbidity prevents inferring that depression modifies ketamine's analgesic effect, and call for randomized trials.
Pharmacology
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Meta-analysis of 22 RCTs including 4161 older surgical patients under general anesthesia, searched across PubMed, Embase and CENTRAL through July 2026.
- Compared perioperative intravenous dexmedetomidine with control for prevention of postoperative delirium, the primary outcome.
- Dexmedetomidine reduced postoperative delirium (RR 0.56, 95% CI 0.47 to 0.66; P<0.00001; I² 24%) and PONV (RR 0.79, 95% CI 0.62 to 0.99; P=0.04).
- Dexmedetomidine was associated with more intraoperative and postoperative bradycardia and more intraoperative hypotension.
- Systematic review and meta-analysis of five randomized trials, totaling 1613 adults aged 60 or older having surgery under regional anesthesia.
- Compared intraoperative dexmedetomidine with propofol, with delirium assessed using CAM or CAM-ICU.
- Delirium occurred in 7.7% of dexmedetomidine patients versus 16.7% with propofol (RR 0.48, 95% CI 0.36-0.64; P < .001), with low heterogeneity (I² = 13.4%).
- The authors conclude dexmedetomidine is associated with less postoperative delirium, and they rated the certainty of evidence as moderate by GRADE.
- This mini review synthesizes a targeted search of pediatric esketamine studies covering analgesia, sedation, propofol injection pain, and emergence delirium or agitation.
- Randomized trials and meta-analyses generally report fewer emergence delirium or agitation events after low intravenous esketamine doses, mostly during sevoflurane adenotonsillectomy.
- Direct dose-comparison evidence in that setting shows increasing benefit up to 0.5 mg/kg intravenously, with no upper efficacy or safety boundary identified.
- The authors conclude that 0.2-0.5 mg/kg IV was the best-studied range for emergence prevention, not a validated therapeutic window, and call for direct dose-timing trials.
- Systematic review and network meta-analysis of 24 RCTs (22 in the meta-analysis, 2,544 patients) in adults admitted to the ICU after non-cardiac surgery.
- Compared dexmedetomidine with normal saline, midazolam, and propofol as postoperative sedation strategies, with ICU delirium as the primary outcome.
- Dexmedetomidine may reduce delirium versus midazolam (RR 0.11, 95% CI 0.02 to 0.80; very low certainty) and versus normal saline (RR 0.46, 95% CI 0.36 to 0.59; low certainty).
- No differences in extubation time or ICU length of stay across strategies, while bradycardia was probably more likely than with propofol (RR 3.03, 95% CI 1.39-6.25; low certainty).
- This scoping review pooled four pharmacokinetic studies including 174 healthy children aged 1 to 18 years receiving perioperative intravenous lidocaine infusion therapy.
- The included studies used different dosing regimens, such as a 1.5 mg/kg bolus followed by 1 mg/kg/h or 2 mg/kg/h, or 1.5 mg/kg/h infusions, so direct comparison was limited.
- Reported plasma lidocaine levels were detectable and below presumed toxic levels, with the highest mean concentration being 2.82 ± 0.65 μg/mL in one study of 22 children.
- The authors concluded that pediatric pharmacokinetic data are extremely limited and that large multicenter studies are needed to define optimal dosing and dose-response relationships.
- This is a pharmacokinetic compartment model, not a clinical study, so no patient sample size is reported.
- The model simulates maternal codeine ingestion across CYP2D6 metabolizer genotypes, including ultra-rapid metabolizers, and transfer of morphine into breastmilk.
- Predicted neonatal morphine concentrations stayed below 1 μg/L regardless of maternal genotype; no confidence intervals or p values are reported.
- The authors conclude that neonatal opioid toxicity from breastfeeding is implausible and that the current ban on codeine for breastfeeding postpartum women should be reviewed.